Immune Therapeutics, Inc. Intellectual Property Contracts & Agreements

8 Contracts & Agreements
Browse by Subcategory
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Amendment No. 3 to License Agreement between the Company and Statera Biopharma, Inc. dated April 15, 2023
License Agreements
Immune Therapeutics, Inc.
Biotechnology
2023
Intellectual Property License Agreement, dated September 30, 2022, between Immune Therapeutics, Inc. and TaiwainJ Pharmaceuticals Co. Ltd
License Agreements
Immune Therapeutics, Inc.
Biotechnology
2022
Agreement dated August 12, 2020 between Immune Therapeutics, Inc. and Cytocom, Inc. assigning all of .Immune Therapeutics right, title and interest in LDN and MENK in Developing...
License Agreements
Immune Therapeutics, Inc.
Biotechnology
2020
PRC Amendment to The Second Amendment to the License Agreement effective December 31, 2018 with Cytocom, Inc. and signed May 12, 2020
License Agreements
Immune Therapeutics, Inc.
Biotechnology
2020
License Agreement dated January 15, 2020 with Forte Biotechnology Intl. Corp
License Agreements
Immune Therapeutics, Inc.
Biotechnology
CO
2020
Second Amendment to License Agreement with Cytocom Inc., effective December 31, 2018 and signed April 8, 2019
License Agreements
Immune Therapeutics, Inc.
Biotechnology
2020
Second Amendment to License Agreement by and between: Cytocom Inc. and Immune Therapeutics Inc., signed April 8, 2019
License Agreements
Immune Therapeutics, Inc.
Biotechnology
2019
Patent License Agreement dated September 24, 2014 between Dr. Jill P. Smith, LDN Research Group LLC and Cytocom, Inc. and related agreements
License Agreements
Immune Therapeutics, Inc.
Biotechnology
2018